Home » Stocks » TLGT

Teligent, Inc. (TLGT)

Stock Price: $0.803 USD 0.063 (8.55%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $0.842 +0.039 (4.81%) Mar 5, 7:59 PM
Market Cap 46.03M
Revenue (ttm) 51.34M
Net Income (ttm) -46.98M
Shares Out 6.08M
EPS (ttm) -8.40
PE Ratio n/a
Forward PE 6.29
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $0.803
Previous Close $0.740
Change ($) 0.063
Change (%) 8.55%
Day's Open 0.747
Day's Range 0.675 - 0.808
Day's Volume 3,310,016
52-Week Range 0.455 - 6.460

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

BUENA, N.J., Feb. 23, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has app...

PRNewsWire - 2 weeks ago

BUENA, N.J., Feb. 16, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has app...

PRNewsWire - 1 month ago

BUENA, N.J., Jan. 28, 2021 /PRNewswire/ -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced a series o...

GlobeNewsWire - 1 month ago

BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received not...

GlobeNewsWire - 2 months ago

BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third q...

InvestorPlace - 2 months ago

Shares of TLGT stock are soaring on Monday ahead of a special shareholder vote to address Teligent's Nasdaq compliance. The post Teligent: 7 Things for Investors to Know About TLGT Stock appea...

GlobeNewsWire - 3 months ago

Scheduled to Reconvene on December 16 , 2020 Company Urgently Encourages Stockholders to Vote

Business Wire - 5 months ago

LOS ANGELES--(BUSINESS WIRE)---- $TLGT #TLGT--TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc.

GlobeNewsWire - 5 months ago

BUENA, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closin...

Seeking Alpha - 6 months ago

Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

BUENA, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the secon...

GlobeNewsWire - 6 months ago

BUENA, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00A...

GlobeNewsWire - 7 months ago

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing...

GlobeNewsWire - 7 months ago

BUENA, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, is pleased to announc...

GlobeNewsWire - 7 months ago

BUENA, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the h...

GlobeNewsWire - 8 months ago

BUENA, N.J., June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that ...

GlobeNewsWire - 9 months ago

BUENA, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today conve...

GlobeNewsWire - 9 months ago

BUENA, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced today that a...

Seeking Alpha - 9 months ago

Teligent's (TLGT) CEO Tim Sawyer on Q1 2020 Results - Earnings Call Transcript

Benzinga - 9 months ago

Shares of Teligent (NASDAQ:TLGT) moved higher by 34% in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 9 months ago

BUENA, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first ...

Seeking Alpha - 10 months ago

Teligent, Inc. (TLGT) CEO Tim Sawyer on Q4 2019 Results - Earnings Call Transcript

Benzinga - 10 months ago

Shares of Teligent (NASDAQ:TLGT) rose 11% in pre-market trading after the company reported Q4 results.

GlobeNewsWire - 10 months ago

BUENA, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the four...

GlobeNewsWire - 1 year ago

BUENA, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced a tra...

GlobeNewsWire - 1 year ago

BUENA, N.J., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has receive...

Seeking Alpha - 1 year ago

Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Teligent (TLGT) delivered earnings and revenue surprises of -100.00% and -6.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Teligent: 100% Upside Based On Revised SOTP With Several Near-Term Catalysts

GlobeNewsWire - 1 year ago

BUENA, N.J., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the pricing...

GlobeNewsWire - 1 year ago

BUENA, N.J., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has filed a prior approval ...

GlobeNewsWire - 1 year ago

BUENA, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Com...

GlobeNewsWire - 1 year ago

BUENA, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Teligent Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced that it has retained SVB Leerink as ...

Seeking Alpha - 1 year ago

TLGT is a rapidly growing micro-cap specialty generic manufacturer with 200%+ upside potential over the next 12-18 months.

Seeking Alpha - 1 year ago

TLGT is a rapidly growing micro-cap specialty generic manufacturer with 200%+ upside potential over the next 12-18 months.

Seeking Alpha - 1 year ago

Teligent's (TLGT) CEO Jason Grenfell-Gardner on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Teligent (TLGT) delivered earnings and revenue surprises of 0.00% and 4.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Teligent (TLGT) delivered earnings and revenue surprises of -50.00% and -20.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Teligent, Inc. (TLGT) CEO Jason Grenfell-Gardner on Q4 2018 Results - Earnings Call Transcript

About TLGT

Teligent, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers,... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1977
CEO
Timothy Sawyer
Employees
252
Stock Exchange
NASDAQ
Ticker Symbol
TLGT
Full Company Profile

Financial Performance

In 2019, Teligent's revenue was $65.90 million, an increase of 0.05% compared to the previous year's $65.87 million. Losses were -$25.12 million, -30.70% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Teligent stock is "Hold" and the 12-month stock price forecast is 1.00.

Price Target
$1.00
Analyst Consensus: Hold